CDC Editorial Note:
The standard technique for detecting virus in mosquitoes is the cell culture plaque assay, which detects only live virus. The real-time PCR technique was first used to detect WNV RNA in mosquitoes in the outbreak investigation during September-November 1999, and produced results consistent with those obtained by plaque assay (CDC, unpublished data, 1999). This experimental assay is highly sensitive for detecting the nucleic acids of pathogens and represents a novel approach for detecting and quantifying viruses.
In the positive pools described in this report, the intensity of the TaqMan signal was in the range consistent with approximately one plaque forming unit (vero cell plaque assay equivalent) according to a standard curve generated in the assay. The ability to detect WNV RNA in the absence of infectious viral particles might be because (1) the virus titer in the overwintering mosquito may be near or below the detectable limits of the plaque assay method; (2) the virus may be noninfectious because of biologic changes in overwintering mosquitoes; (3) the virus may have been killed during the collection and processing of specimens; (4) noninfectious viral RNA may persist in the mosquitoes; or (5) the results were false positives. Attempts to isolate virus from these pools are continuing using other isolation systems.
It is unknown whether WNV will persist in the New York area. Overwintering mosquitoes were difficult to locate, and intact WNV has not been identified. Three fourths of all specimens were obtained from the Fort Totten site. Surveillance of overwintering mosquitoes will continue.
WNV can be transmitted from parent to offspring mosquitoes, 5 and this vertical transmission has been documented in field populations of Culex univittatus in Kenya. 6 The role of vertical transmission in the maintenance cycles of this virus is uncertain. A related flavivirus (St Louis encephalitis virus) may persist through the winter in vertically infected, diapausing Culex mosquitoes, but it is probably a rare occurrence if it occurs in nature. 7 The findings in this report demonstrate the value of continued vigilance in detecting the re-emergence of WNV. Counties where WNV transmission occurred in 1999 should monitor closely for WNV and conduct mosquitocontrol activities in the spring to reduce the potential for recurrence and amplification of WNV. Mosquitocontrol activities include reducing the number of mosquito breeding sites, particularly around homes and suburban and urban areas, and applying larvicide to Culex larval habitats early.
In December 1999, CDC announced availability of funds to suppot WNV surveillance, prevention, and control programs. The 19 state and local health departments eligible to apply for these funds represent areas where WNV transmission already has occurred or where transmission would be more likely to occur based on bird migration patterns. The focus of these cooperative agreements enables state and local health departments to increase surveillance activities and enhance laboratory capacity for detecting WNV and other arbovi-
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ruses. In 2000, surveillance activities will be focused on determining whether WNV survived the winter and, if so, to ascertain its geographic distribution along the Atlantic and Gulf coasts. COMMUNITY-BASED AND STATE-BASED IMmunization registries are confidential, population-based, computerized information systems that contain data about children's vaccinations 1 and represent an important tool to increase and sustain high vaccination coverage. Immunization registries consolidate vaccination records for children from multiple providers, provide a vaccination needs assessment for each child, generate reminder and recall vaccination notices, produce an official vaccination record, and provide practice-specific and community-based vaccination coverage assessments. One of the Healthy People 2010 national objectives is to increase to 95% the proportion of children aged less than 6 years who are enrolled in a fully operational populationbased immunization registry. 2 To assess the status of immunization registry development, CDC analyzed data from the 1999 Immunization Registry Annual Report (IRAR) of 64 jurisdictions (grantees) that receive federal immunization funds under section 317d of the Public Health Service Act. Findings from this analysis indicate that substantial progress has been made in the United States in developing and implementing community-based and statebased immunization registries.
Progress in
The IRAR was a self-administered questionnaire, sent to immunization program managers, that measured the degree of enrollment of a registry's target population (i.e., percentage of children in the catchment area with vaccinations recorded in the registry and percentage of public and private providers submitting records to the registry) and the implementation of 12 functional standards considered essential for immunization registry operation. The 12 standards were identified through a survey of immunization program managers and registry developers. Focus group research with the managers and developers was conducted to ensure consensus about the importance of these standards. Key elements associated with each standard then were identified and used to establish more sensitive registry development and implementation progress measures. In addition, the IRAR collected information on immunization registry links with other information systems.
In 1999, the 64 jurisdictions (50 states, the District of Columbia, Chicago, Houston, New York City, Philadelphia, San Antonio, American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, Palau, Puerto Rico, and the U.S. Virgin Islands) were mailed the questionnaire; 62 (97%) responded. Of the 62, three (5%) grantees (all commonwealths or territories) reported no registry activity, 16 (26%) grantees reported planning or pilot-testing of registries, and 43 (69%) grantees reported implementing registries.
Data from 37 of the 43 grantees implementing registries indicated that approximately 32% (mean = 50%; median=54%) of estimated target children aged 0-5 years in the grantees' catchment areas had at least two doses of vaccine recommended by the Advisory Committee on Immunization Practices and that the information was recorded in a registry's database. Data from 42 grantees indicated that 46% (median = 96%) of public providers and 13% (median=15%) of private providers had submitted records to a registry.
Of the 43 grantees, all had implemented at least one key element on four of the 12 registry functional standards (i.e., electronic data storage of core data elements, protection of confidential medical information, recovery of lost data, and consolidation of vaccination records from multiple providers). Three (7%) grantees reported implementing at least one key element in each standard. However, none had implemented all key elements of the 12 functional standards.
Forty-one (95%) of the 43 grantees reported immunization registry links with at least one other health-care program; of these, 25 (61%) were linked to their state's vital records department. Links to birth certificates indicate that these registries are population-based (not provider-based or practice-based). The median number of weeks from birth to establishing a registry record was 5 weeks (range: 1-12 weeks). 
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The 1999 IRAR represents the first attempt to quantify and evaluate state-based and community-based immunization registry development in the United States. These data suggest that substantial progress has been made in U.S. communities and states in enrolling children, recruiting providers, and implementing registry functional standards.
Substantial challenges remain in developing registries. One of the greatest challenges is balancing the need to protect the privacy of patients, providers, and other users of these systems with the need to gather and share information to protect the public health and provide clinical benefit to persons. In response to recommendations of the National Vaccine Advisory Committee (NVAC) 1999 report, Development of Community-and State-Based Immunization Registries, 1 CDC developed specifications for privacy protection of registry participants and for the confidentiality of information contained in FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION ©2000 American Medical Association. All rights reserved. a registry. These specifications were approved by NVAC in February 2000. They are consistent with privacy regulations required by the Health Insurance Portability and Accountability Act of 1996. 3 Ensuring high levels of public and private provider participation in registries is a critical prerequisite to complete and accurate electronic vaccination records. In an increasingly mobile environment, where approximately 20% of children move by age 2 years, 4 appropriate vaccination decisionmaking often depends on aggregating vaccination histories from multiple providers. Solving technical and operational challenges of sharing vaccination information between registries that may use different computer hardware and software is critical.
The findings in this report are subject to at least two limitations. First, because the IRAR relies on self-reported data, some bias is expected. On-site verification of these data is planned to ensure a more accurate assessment of registry development. Second, because only immunization program grantees were surveyed, these data underestimate the degree of registry activity occurring in the United States. Survey respondents reported 84 additional immunization registries implemented at the local level. However, data collected on these systems suggest that many are not population-based.
Since 1994, more than $178 million in federal funds have been awarded to state and local health departments to support the development and implementation of immunization registries. 5 Fiscal savings associated with registries include avoiding duplicative vaccinations, assuring maximal returns for appointments through the use of reminder/recall notices, reducing vaccine wastage, avoiding manual generation of vaccination certificates, and avoiding manual review of multiple records to establish the Health Plan Employer Data and Information Set (HEDIS) indices. Immunization registries also can play an important role in increasing vaccine safety and monitoring adverse events because core registry data elements include vaccine date and type, manufacturer, and lot number. Registry data in Arkansas and California have been used to identify and revaccinate children who received vaccinations from sub-potent vaccine lots or an inadequate dosage of vaccine, 6 During 1950-1996, age-standardized stroke death rates declined 70% for the entire U.S. population 2 ; however, the decline varied among racial/ethnic populations. 1 The estimated number of stroke deaths by race/ethnicity and age illustrate the differences in stroke mortality that may be used to direct prevention efforts. This report presents an analysis of stroke mortality by age and racial/ethnic group; the findings indicate that for persons aged 35-64 years, excess stroke deaths and higher risk for stroke mortality occurred among members of U.S. racial/ethnic minority populations than among the non-Hispanic white population.
Excess death is the difference between the number of deaths observed in a racial/ethnic group and the number of deaths that would have occurred in that group if it had the same death rate as the non-Hispanic white population. 3 Relative risk is the ratio of the stroke death rate of the minority group compared with that of the non-Hispanic white population accounting for differences in population size. The 1997 death certificate data were used to determine excess death and relative risk for stroke mortality by racial/ethnic group (nonHispanic blacks, Hispanics, American Indians/Alaska Natives [AIs/ANs], and Asians/Pacific Islanders [As/PIs]) and by age group (35-44, 45-54, 55-64, 65-74, 75-84, and 85 years). Non-Hispanic whites in each age group were the referent group. Observed stroke deaths were those for which the underlying cause of death listed on the death certificate by a physician, medical examiner, or coroner was International Classification of Diseases, Ninth Revision (ICD-9), codes 430-438. Demographics on death certificates (e.g., age, race, and ethnicity) are reported by funeral directors usually on the basis of observation or are provided by family members. National mortality statistics were based on information from death certificates filed in state vital statistics offices and were compiled by CDC.
1 Expected deaths were calculated by multiplying the number of persons in each age-specific racial/ethnic group by the death rates in the corresponding non-Hispanic white group. Agespecific excess deaths were calculated by subtracting the observed deaths from the expected deaths for each age-specific group. Relative risks were calculated by dividing the death rate for each agespecific group by the corresponding death rate for non-Hispanic whites. The number of excess stroke deaths was largest for non-Hispanic blacks and As/PIs aged 35-84 years (6370 and 220, respectively); no excess stroke deaths occurred among non-Hispanic blacks and 
The findings in this report highlight the excess number of stroke-related deaths among nonHispanic black, AIs/ANs, As/PIs, and Hispanics compared with nonHispanic white adults, especially among those aged 35-64 years. Excess deaths among racial/ethnic groups compared with non-Hispanic whites might be the result of greater prevalence of risk factors for stroke (e.g., obesity, uncontrolled hypertension, physical inactivity, poor nutrition, diabetes, and smoking) and other factors (e.g., lower socioeconomic status, predisposition for greater disease severity, and poor survival at younger ages). 4, 5, 7 Excess stroke deaths also may result from barriers to adequate medical care, including preventive, diagnostic, and therapeutic interventions 4 and health insurance coverage. 5 Non-Hispanic blacks, As/PIs, and Hispanics have lower rates of healthcare coverage than non-Hispanic whites 6 ; however, availability of health insurance or high-quality care does not indicate complete access to or use of medical care. Other barriers include lack of trust in the health-care system and fear of invasive medical procedures, 5 transportation difficulties, and unfamiliarity with early warning signs of stroke. 5 Despite progress in preventing and treating risk factors for stroke (e.g., increases in the use of antihypertensive therapy), the increasing prevalence of heart disease, diabetes, and obesity in the United States has increased the relative risk for stroke, particularly among blacks. 4 Racial/ethnic differences in susceptibility to hemorrhagic and ischemic stroke subtypes are related strongly to uncontrolled high blood pressure and smoking. 7 The increased frequency of intracerebral hemorrhages among blacks is attributable mostly to greater occurrence of hypertension. 7 The greater number and severity of strokes in some racial/ ethnic groups may be associated with differences in hypertension prevalence and control in all age groups. 8 The data in this report are subject to at least four limitations. First, misclassification of race/ethnicity on death certificates and in the population census may result in understated reported death rates among AIs/ANs, As/PIs, and Hispanics. For the same reason, death rates for black and white populations may be overstated. 9 Second, although variations among subpopulations may exist, the burden of stroke deaths is not shown for subgroups within the larger racial/ethnic groups. Third, the smaller sizes of populations of As/PIs and AIs/ ANs can result in unstable estimates and produce overstated or understated death rates from year to year. Finally, this analysis did not control for stroke risk factors.
Reducing stroke mortality among groups at highest risk largely depends on reaching them before unhealthy behaviors are adopted. Public health interventions can be community-based or can target persons at greatest risk. For example, in 1999, CDC began Racial and Ethnic Approaches to Community Health 2010 (REACH), community-based, culturally appropriate approaches to reduce cardiovascular disease and stroke among racial/ ethnic populations. The national Brain Attack Coalition educates the public about the early warning symptoms of stroke to increase the likelihood of early diagnosis and prompt, effective treatment. Targeted research and evaluation among racial/ethnic populations may help identify differences among subpopulations related to lower socioeconomic or educational levels or related to adverse environmental factors. CDC is working with 11 statebased prevention and education programs that aim to reduce cardiovascular disease and stroke by improving nutrition, increasing physical activity, and promoting healthy behaviors. 2-4 These guidelines recommend using either a screening-based or a risk-based strategy to identify women who should receive intrapartum antimicrobial prophylaxis. To assess adoption of the GBS disease prevention guidelines, the Connecticut and Minnesota state health departments surveyed prenatal-care providers during JanuaryApril 1998. This report presents the survey findings, which indicate that most prenatal-care providers in Connecticut and Minnesota have adopted perinatal GBS disease prevention policies and that strategy choice may vary by state and provider type.
Adoption of
In Connecticut, surveys were mailed to all (n=576) licensed obstetricians/ gynecologists (OBs). Group practices were allowed to submit a single response for all members. A second mailing was sent to nonrespondents. A sample of nonrespondents was then contacted by telephone to determine reasons for nonresponse. After eliminating providers from the sample who did not deliver prenatal care and those who were represented by a response from another provider in their practice, the final response rate was 77% (250 of 323). In Minnesota, surveys were mailed to a random sample of approximately 50% of practicing OBs, a random sample of approximately 25% of family physicians (FPs) who indicated on their licensure application they provided prenatal care, and all certified nurse midwives (CNMs). After three mailings, 431 (77%) of those sampled responded. The response rate was similar for all three provider groups.
In 1998, most prenatal-care providers in Connecticut and Minnesota reported that their practices had a perinatal GBS disease prevention policy, although most practices did not have a written policy. Practices in Connecticut were more likely than those in Minnesota (PϽ.001) to have a GBS disease prevention policy, primarily because of the relatively low percentage of Minnesota family practices with a policy. More than 90% of individual providers from both states reported having a GBS disease prevention policy. Most providers in Connecticut chose a screening-based strategy (72%), and most in Minnesota chose a risk-based strategy (55%). When the analysis was limited to OBs in both states, OBs in Connecticut were more likely than OBs in Minnesota to choose a screeningbased strategy (PϽ.001).
Of providers who used a screeningbased strategy, 71% from Connecticut and 76% from Minnesota collected specimens from both the vagina and rectum, as recommended by the consensus guidelines. Providers using the screening-based strategy from Connecticut (82%) and Minnesota (80%) obtained cultures within 1 week of the recommended 35-37 weeks' gestation. Of providers who used a riskbased strategy in Minnesota, 80% indicated that they would administer intrapartum prophylaxis for all five of the high-risk criteria (i.e., previous infant with invasive GBS disease, GBS bacteriuria during the current pregnancy, delivery at less than 37 weeks' gestation, duration of rupture of membranes Ն18 hours, and intrapartum fever Ն100.4°F [Ն38°C]) as specified in the consensus guidelines. Questions about indications for prophylaxis under the risk-based strategy were not asked in the Connecticut survey.
In Minnesota, differences were observed between the responses of FPs compared with OBs or CNMs. OBs and CNMs were more likely than FPs (PϽ.001) to report that their practices had a GBS disease prevention policy. Individual FPs were less likely to choose a risk-based strategy or to use penicillin for intrapartum prophylaxis (PϽ.001 for all comparisons except strategy choice between FPs and OBs). OBs were significantly more likely than either CNMs (91% vs 46%, P=.001) or FPs (91% vs 73%, P=.03) to report collecting specimens from both the vagina and rectum. FPs were less likely to respond that they would follow all five recommended indications than either OBs (69% vs 89%, P = .004) or CNMs (69% vs. 84%, P =.04). 
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Perinatal GBS disease is largely preventable through targeted use of intrapartum antibiotic prophylaxis. 2 Since the release of the 1996 consensus prevention guidelines, the incidence of perinatal GBS disease has declined in the United States. 5 Prenatalcare providers play a critical role in preventing GBS disease. The findings in this report suggest that most prenatalcare providers in Connecticut and Minnesota have adopted one of the two GBS disease prevention strategies recommended in the consensus guidelines and that strategy choice may vary by state and provider type. Pregnant women should discuss GBS disease prevention with their prenatal-care providers to optimize GBS disease prevention opportunities.
In Minnesota, FPs providing prenatal care were less likely than OBs or CNMs to report that their practices have a GBS disease prevention policy and to report following all the guidelines within either the risk-based or screening-based strategy. These findings suggest that additional efforts are needed to inform FPs in Minnesota about GBS disease prevention recommendations. FPs also were less likely to use penicillin, the recommended intrapartum antibiotic. Although ampicillin is an acceptable alternative, 2 penicillin is preferred because it has a narrower spectrum of activity and is therefore less likely to promote antimicrobial resistance. This study was conducted before the recent shortage of penicillin G for intravenous administration. A new supplier has been identified, and penicillin G should be more available for intrapartum prophylaxis. 6 In 1997, hospital obstetric departments were surveyed in both Connecticut and Minnesota about perinatal GBS disease prevention policies. 7 In both states, the percentage of OBs providing prenatal care who reported adopting a perinatal GBS disease prevention policy was higher than the percentage of hospitals with a policy. Hospitals may leave decisions about GBS disease prevention activities to prenatal-care providers. Efforts to expand perinatal GBS disease prevention activities should be directed at both hospitals and prenatalcare providers. 8 Although the surveys presented in this report were not designed to measure provider practices, the results suggest that prenatal-care providers are aware of the recommendations outlined in the consensus guidelines. The screening-based strategy relies on appropriate and accurate specimen collection by prenatalcare providers. Most providers in Connecticut and in Minnesota using the screening-based strategy reported collecting specimens from both the vagina and rectum. Collection site is important because vaginal/rectal specimens improve group B Streptococcus isolation rates by 40% over vaginal specimens alone. 9, 10 At least 80% of prenatal-care providers using the screening-based strategy in both states also reported collecting specimens at appropriate times. The risk-based strategy depends on prenatalcare providers identifying and administering prophylaxis to women at increased risk for delivering an affected infant. In Minnesota, 80% of prenatalcare providers using the risk-based strategy reported following the recommended indications for intrapartum antibiotic prophylaxis.
The findings in this report are subject to at least two limitations. First, because the surveys were conducted in only two states, the results might not be generalizable to other states. Second, the surveys measured only the reported practices of prenatal-care providers and not the services actually rendered.
GBS Measles is a notifiable disease in the Netherlands, and cases that occurred during this outbreak were reported by physicians to the local MHS as part of routine surveillance. The vaccination status of ill persons was reviewed based on written records kept by reporting physicians and sent to the vaccination registry. In April 1999, the first cluster of measles cases occurred, followed by the reported elementary school outbreak in June. No cases of measles with onset in May were reported, and transmission was low during June and July. When schools reopened in August, the number of cases increased. The outbreak peaked during October-November, then decreased rapidly. As of February 4, the last reported cases had onset during the week of January 16. Since then, the number of reported cases has decreased substantially, suggesting that the outbreak is ending.
From April 15, 1999, to February 4, 2000, 2961 cases of measles were reported in 35 (67%) of the country's 52 MHSs; 2317 (78%) were reported by 10 MHSs. All reporting municipalities have large communities affiliated with the religious group. Of the 105 case-patients tested for measles immunoglobulin type M, 100 (95%) had serologically confirmed measles.
Complications among acute measles case-patients were assessed by telephone follow-up with reporting physicians; 510 (17%) cases had one or more complications and/or hospitalizations. Three patients died as the result of measles complications: one child aged 2 years had an underlying cardiac disorder and subsequent cardiac failure, one child aged 3 years developed myocarditis, and one adolescent aged 17 years developed kidney failure and acute respiratory distress syndrome. Sixty-eight (2.2%) persons were reported hospitalized: 37 (1.2%) for pneumonia, seven FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION
